Cargando…

The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma

Mostrar otras versiones (1)

BACKGROUND: Cholangiocarcinoma is an aggressive malignancy with limited therapeutic options. MEK inhibition and antiangiogenic therapies have individually shown modest activity in advanced cholangiocarcinoma, whereas dual inhibition of these pathways has not been previously evaluated. We evaluated t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shroff, Rachna T, Yarchoan, Mark, O'Connor, Ashley, Gallagher, Denise, Zahurak, Marianna L, Rosner, Gary, Ohaji, Chimela, Sartorius-Mergenthaler, Susan, Subbiah, Vivek, Zinner, Ralph, Azad, Nilofer S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520097/ https://www.ncbi.nlm.nih.gov/pubmed/28441383 http://dx.doi.org/10.1038/bjc.2017.119

Ejemplares similares

The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma
por: Shroff, Rachna T, et al.
Publicado: (2018)

Trametinib: a MEK inhibitor for management of metastatic melanoma
por: Lugowska, Iwona, et al.
Publicado: (2015)

Isotretinoin for the treatment of severe acneiform eruptions associated with the MEK inhibitor trametinib
por: Caruana, Marco, et al.
Publicado: (2020)

Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors
por: Dembla, Vikas, et al.
Publicado: (2017)

The MEK Inhibitor Trametinib Improves Outcomes following Subarachnoid Haemorrhage in Female Rats
por: Bömers, Jesper Peter, et al.
Publicado: (2022)

Pharmacokinetics and tolerability of the dual TORC1/2 inhibitor sapanisertib in combination with the MEK inhibitor trametinib in dogs
por: Wei, Bih-Rong, et al.
Publicado: (2022)

The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo
por: Booth, Laurence, et al.
Publicado: (2017)

BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia
por: Seipel, Katja, et al.
Publicado: (2021)

The MEK Inhibitors Trametinib and Cobimetinib Induce a Type I Interferon Response in Human Keratinocytes
por: Lulli, Daniela, et al.
Publicado: (2017)

ERRα suppression enhances the cytotoxicity of the MEK inhibitor trametinib against colon cancer cells
por: Zhou, Sheng, et al.
Publicado: (2018)

Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis
por: Aaroe, Ashley, et al.
Publicado: (2023)

PB2282: MEK-KINASE INHIBITOR (TRAMETINIB) AS A TREATMENT OPTION FOR HAIRY CELL LEUKEMIA
por: Smirnova, Svetlana, et al.
Publicado: (2023)

Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer
por: BALL, DOUGLAS W., et al.
Publicado: (2015)

A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies
por: Piha-Paul, Sarina A, et al.
Publicado: (2021)

The MEK Inhibitor Trametinib Suppresses Major Histocompatibility Antigen-mismatched Rejection Following Pancreatic Islet Transplantation
por: Tada, Seiichiro, et al.
Publicado: (2020)

ONC201 and an MEK Inhibitor Trametinib Synergistically Inhibit the Growth of Triple-Negative Breast Cancer Cells
por: Lim, Bora, et al.
Publicado: (2021)

Head-to-Head Comparison of BRAF/MEK Inhibitor Combinations Proposes Superiority of Encorafenib Plus Trametinib in Melanoma
por: Schulz, Alexander, et al.
Publicado: (2022)

Successful treatment of refractory chylothorax with MEK inhibitor trametinib in a child with Noonan syndrome: case report
por: Hribernik, Ines, et al.
Publicado: (2023)

MEK inhibition with trametinib is a successful therapy in ganglioglioma
por: Daniel, Eliza Baird, et al.
Publicado: (2020)

Pazopanib and Trametinib as a Synergistic Strategy against Osteosarcoma: Preclinical Activity and Molecular Insights
por: Chiabotto, Giulia, et al.
Publicado: (2020)

Pharmacokinetic Interaction Between the MEK1/MEK2 Inhibitor Trametinib and Oral Contraceptives Containing Norethindrone and Ethinyl Estradiol in Female Patients With Solid Tumors
por: Arkenau, Hendrik‐Tobias, et al.
Publicado: (2022)

MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX)
por: Kawaguchi, Kei, et al.
Publicado: (2017)

Structural basis for the action of the drug trametinib at KSR-bound MEK
por: Khan, Zaigham M., et al.
Publicado: (2020)

MEK inhibition suppresses B regulatory cells and augments anti-tumor immunity
por: Yarchoan, Mark, et al.
Publicado: (2019)

Co-Treatment with Panitumumab and Trastuzumab Augments Response to the MEK Inhibitor Trametinib in a Patient-Derived Xenograft Model of Pancreatic Cancer()
por: Lindberg, James M., et al.
Publicado: (2014)

Antitumor activity of the MEK inhibitor trametinib on intestinal polyp formation in Apc(Δ716) mice involves stromal COX-2
por: Fujishita, Teruaki, et al.
Publicado: (2015)

Bim, Puma and Noxa upregulation by Naftopidil sensitizes ovarian cancer to the BH3-mimetic ABT-737 and the MEK inhibitor Trametinib
por: Florent, Romane, et al.
Publicado: (2020)

LGG-30. TRAMETINIB-ASSOCIATED HYPONATREMIA IN A CHILD WITH LOW GRADE GLIOMA IS NOT SEEN FOLLOWING TREATMENT WITH ALTERNATIVE MEK INHIBITOR
por: Lazow, Margot A, et al.
Publicado: (2020)

Antitumoral Activity of the MEK Inhibitor Trametinib (TMT212) Alone and in Combination with the CDK4/6 Inhibitor Ribociclib (LEE011) in Neuroendocrine Tumor Cells In Vitro
por: Jin, Xi-Feng, et al.
Publicado: (2021)

Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction
por: Unsworth, Amanda J., et al.
Publicado: (2018)

Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months
por: Marconcini, Riccardo, et al.
Publicado: (2017)

The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib
por: Booth, Laurence, et al.
Publicado: (2019)

STUMP un“stumped”: anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion
por: Subbiah, Vivek, et al.
Publicado: (2015)

Computational Study on the Effect of Inactivating/Activating Mutations on the Inhibition of MEK1 by Trametinib
por: Zhu, Jingxuan, et al.
Publicado: (2020)

ET-09 ACQUIRED MALIGNANT BEHAVIORS OF NPE6-PDT-SURVIVED GLIOBLASTOMA CELLS ARE SUPPRESSED BY USING MEK1/2 INHIBITOR TRAMETINIB
por: Kobayashi, Tatsuya, et al.
Publicado: (2019)

Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus with MEK Inhibitor Trametinib in Some BRAF or KRAS-Mutated Colorectal or Lung Carcinoma Models
por: Zhou, XuSha, et al.
Publicado: (2021)

LGG-03. EXPLORING THE SIGNALING NETWORK INVOLVED IN MAPK PATHWAY INHIBITION BY THE MEK INHIBITOR TRAMETINIB IN BRAF-FUSION-DRIVEN PEDIATRIC PILOCYTIC ASTROCYTOMA
por: Sigaud, Romain, et al.
Publicado: (2023)

A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation
por: Piha-Paul, Sarina A., et al.
Publicado: (2023)

Pazopanib and anti-VEGF therapy
por: Drabkin, Harry A
Publicado: (2010)

Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma
por: Prado, C M M, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_rf9gtivh89sc90cej8o4dpiopj